Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8986513 | 0.96 | MEN1 (0.38) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL19658041 | 0.81 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL24733052 | 0.81 | MEN1 (0.33) | MEN1KMT2AMAPK1 | |
| SCHEMBL24732987 | 0.81 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL25790341 | 0.78 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL24733089 | 0.78 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL17914505 | 0.78 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL22525224 | 0.73 | — | — | |
| SCHEMBL15955847 | 0.72 | CYP1A2 (0.39) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL339999 | 0.72 | CA12 (0.38) | CA12CA1CA2CA9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109012747-B | Application of copper (I) coordination polymer | 苏州大学 | 2021-02-12 | — | — | CN | claimed |
| CN-109012747-A | A kind of purposes of copper (I) coordination polymer | 苏州大学 | 2018-12-18 | — | — | CN | claimed |
| CN-105503946-B | The manufacturing method of hydroxymethyl phosphonic acid ester, polyurethane foam formation composition, polyurethane foam and the product being made from it | ICL-IP美国公司 | 2018-10-12 | — | — | CN | claimed |
| US-9708242-B2 | Method of manufacturing nitrone compound | NATIONAL CHUNG CHENG UNIVERSITY (TW) | 2017-07-18 | — | — | US | claimed |
| EP-2243769-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE FLUOROAMINE | CENTRAL GLASS CO LTD (JP) | 2017-06-28 | — | — | EP | claimed |
| US-20170036989-A1 | Method of Manufacturing Nitrone Compound | NATIONAL CHUNG CHENG UNIVERSITY | 2017-02-09 | — | — | US | claimed |
| CN-105968374-A | Copper (I) coordination polymer and preparation method and application thereof | 苏州大学 | 2016-09-28 | — | — | CN | claimed |
| CN-105949072-A | Preparation method and intermediate of beta-substituted amino-gamma-substituted aryl butyric acid | 苏州敬业医药化工有限公司 | 2016-09-21 | — | — | CN | claimed |
| CN-105503946-A | Method for making hydroxymethylphosphonate, polyurethane foam-forming compositions, polyurethane foam and articles made therefrom | ICL-IP America Inc | 2016-04-20 | — | — | CN | claimed |
| CN-102256987-B | Hydroxymethylphosphonate, polyurethane foam-forming compositions, polyurethane foams, and methods of making articles made therefrom | ICL-IP AMERICA INC. (US) | 2016-01-13 | — | — | CN | claimed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | claimed |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | claimed |
| EP-1706408-A2 | PROCESSES FOR THE PREPARATION OF PYRAZOLO[1,5- A] -1,3,5-TRIAZINES AND INTERMEDIATES THEREOF | Bristol-Myers Squibb Pharma Company (US) | 2006-10-04 | — | — | EP | claimed |
| US-20050153074-A1 | Method of activating a silicon surface for subsequent patterning of molecules onto said surface | SONY DEUTSCHLAND GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| US-20050143380-A1 | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2005-06-30 | — | — | US | claimed |
| WO-2005051954-A2 | PROCESSES FOR THE PREPARATION OF PYRAZOLO[1,5-a]-1,3,5-TRIAZINES AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-09 | — | — | WO | claimed |
| EP-1538481-A1 | A method of activating a silicon surface for subsequent patterning of molecules onto said surface | Sony International (Europe) GmbH (DE) | 2005-06-08 | — | — | EP | claimed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | claimed |
| EP-0507896-A1 | HAIR-FIXING AGENT. | WELLA AG (DE) | 1992-10-14 | — | — | EP | claimed |
| WO-1992007545-A1 | HAIR-FIXING AGENT | WELLA AKTIENGESELLSCHAFT (DE) | 1992-05-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | MEN1 3394/4885KMT2A 1551/4885CA12 4774/4885 |
| US-20170036989-A1 | Method of Manufacturing Nitrone Compound | NOS1, NOS2, NOX5 | MEN1 2003/4885KMT2A 887/4885CA12 4343/4885 |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | MEN1 3394/4885KMT2A 1551/4885CA12 4774/4885 |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | MEN1 3394/4885KMT2A 1551/4885CA12 4774/4885 |
| US-20050143380-A1 | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof | CRHR1, CRH, CRHR2 | MEN1 1780/4885KMT2A 4020/4885CA12 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.